Brokers name 2 ASX shares to buy this week

Breville Group Ltd (ASX:BRG) is one of two ASX shares that brokers think you should buy this week.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I feel it is fair to say that sentiment can mean a lot in the share market. Shares that are out of favour with brokers can find it hard to get out of a downward trend. Whereas shares that are in favour with brokers and being recommended with a buy rating can climb higher and higher thanks to the positive sentiment.

For this reason I like to keep a close eye on what brokers are saying about shares on the Australian Stock Exchange. The good news for shareholders of these two companies is that according to the brokerage arm of Commonwealth Bank of Australia (ASX: CBA), certain brokers have just upgraded them to a buy recommendation.

Breville Group Ltd (ASX: BRG)

I feel Breville is one of the most underrated shares on the ASX, so it is great to see it finally find favour with brokers. In its half year report Breville reported a 12.7% increase in revenue year-on-year to $331 million and bottom line growth of 4% to $31 million.

Thanks to the current housing market boom, I believe Breville will see solid organic growth from its Australian operations. But its international operations are likely to be the real catalyst for growth.

The company's growing exposure to the United States is a key reason why I expect it to perform well this year. In its half-year results the North American segment produced an increase in both revenue and earnings of 30.8% and 39.9%, respectively.

If it can carry on this strong performance for the full year then I would expect to see the share price climb higher. A further bonus is the fact it is expected to pay an estimated fully franked FY 2016 dividend of 3.6%.

REVA Medical Inc (ASX: RVA)

REVA is a clinical stage medical device company located in San Diego in the United States. It has developed bioresorbable scaffolds which provide an alternative to metal stents.

Metal stents are small tube-like devices that are permanently implanted into an artery to treat coronary artery disease. Whereas REVA's bioresorbable scaffolds are essentially designed to do the same job, then disappear naturally from the body over a period of time.

REVA has just received positive six-month results from the first group of patients in the clinical trial of the company's scaffolds. It is of course early days, but this is a great step forward for the company. The global coronary stents market has been estimated by Transparency Market Research to be worth over US$8.3 billion per year by 2019.

In my opinion this is definitely one for the watchlist, but may be a little too speculative at this stage for my personal liking.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »